Regulators and doctors must work together to ensure safety of biologic medicines

December 15, 2011

By Dr. Marcy Zwelling-Aamot, chairperson of the Board of the American Academy of Private Physicians (AAPP) The Hill  The U.S. Food and Drug Administration (FDA) is holding an important public meeting today on its proposed biosimilar user fee program recommendations.  This meeting is a major step in making biosimilars available for the first time in […]

Read More

Emerging patient safety issues under health care reform: follow-on biologics and immunogenicity

December 7, 2011

Emerging patient safety issues under health care reform: follow-on biologics and immunogenicity By Bryan A. Liang and Timothy Mackey Therapeutics and Clinical Risk Managment Abstract: US health care reform includes an abbreviated pathway for follow-on biologics, also known as biosimilars, in an effort to speed up access to these complex therapeutics. However, a key patient […]

Read More

Alliance for Safe Biologic Medicines Launches Webinar Series

November 12, 2011

Alliance for Safe Biologic Medicines Launches Webinar Series Starting in November, The Alliance for Safe Biologic Medicines will host several webinars on biologic and biosimilar medicines, hosted by Alliance Chairman Dr. Richard Dolinar. Registration is free! Biologics 101: What are biologics and why should you care? Thursday, November 17, 2:30 PM EST Click here to […]

Read More

About the FDA and Biosimilars

November 4, 2011

By Bruce Rubin MedPage Today Although politicians and patients may debate the benefits and drawbacks of the U.S. healthcare system, when it comes to inventing new medical technologies and discovering life-saving treatments, no other nation matches the U.S. in terms of innovation and delivery of care. One reason the U.S. is so successful is that […]

Read More

FDA’s “Pathway on Biosimilars” Forthcoming

October 6, 2011

The FDA’s Janet Woodcock recently appeared on BioCenturyTV and in a web exclusive she addresses a potential ‘biosimilars pathway’. Though she declined to comment on the specific clinical and nonclinical standards, she made clear that the approval pathway for a biosimilar is different from that of a biologic. She also said that biosimilar interchangeability is […]

Read More

Drug costs, benefits must align

October 5, 2011

Dr. David Charles, Chairman, Alliance for Patient Access The Tennessean In 1993, a drug just approved by the Food and Drug Administration was highlighted in a Fortune magazine article under the eye-catching headline “Fortune Products of the Year.” The drug was Betaseron. And while the headline was ambitious, the new drug was a medical triumph. […]

Read More

New medicines bring hope, safety concerns

September 10, 2011

By Kara Nett Hinckley, Public Policy Coordinator, Colorado Chronic Care Collaborative Denver Post How many of us have watched a loved one or friend suffer from a serious illness and wished for a miracle treatment that could help them with their struggle? Biologic drugs are not miracles, but they are a new, often better way […]

Read More

Patient safety is essential for new cancer meds

August 25, 2011

By Andrew Spiegel, CEO, Colon Cancer Alliance The Patriot-News The lead article in this month’s New England Journal of Medicine was a perspective piece written by key Food and Drug Administration officials on the development of America’s biosimilars program. Biosimilars are the imitative versions of biologic medicines, the miracle drugs to treat serious conditions such […]

Read More

Is the FDA writing a recipe for the failure of biosimilars in the U.S.?

August 8, 2011

FierceBiotech By John Carroll Will FDA officials raise the regulatory bar on biosimilars so high they can’t be competitive in the U.S.?  Longtime researcher and Parexel consultant Dr. Saurabh Aggarwal seems to think there’s a very high risk of that. In an interview with Scientific American blogger Khadijah Britton, Aggarwal says that the FDA’s latest […]

Read More

Biosimilars: US payers “will want more data than FDA”

August 5, 2011

PharmaTimes By Lynne Taylor To feel comfortable with generic biologics (biosimilars), US payers are likely to require more clinical information than what might be accepted by the Food and Drug Administration (FDA) for approvals, a new report suggests. For example, FDA approval of biosimilar versions of monoclonal antibodies (MAbs) for oncology indications will not allay […]

Read More